Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis

Metabolism: Clinical and Experimental · Published 2026-06-01 · DOI 10.1016/j.metabol.2026.156657

Authors (11)

Pengkai Wu, Abdukahar Kiram, Yong Zhu, Ziqiao Yuan, Ziqi Zhu, Zehua Zhang, Yipeng Bai, Lei Zhao, Xihua Li, Zhijian Li, Dengqiu Xu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wu, P., Kiram, A., Zhu, Y., et al. (2026). Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis. Metabolism: Clinical and Experimental. https://doi.org/10.1016/j.metabol.2026.156657

Related articles

• Dynamic regulation of circulating endotrophin by changes in fat mass in humans · Metabolism: Clinical and Experimental · 2026 · Same journal
• Cytochrome P450 2E1 deficiency alters hepatic mitochondria and impairs liver organoid formation · Metabolism: Clinical and Experimental · 2026 · Same journal
• Metabolomic signatures of type 2 diabetes and mortality: Methodological considerations and unresolved questions · Metabolism: Clinical and Experimental · 2026 · Same journal
• STAU1 fine-tunes adipose thermogenesis by regulating Ucp1 mRNA stability · Metabolism: Clinical and Experimental · 2026 · Same journal
• Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis · Metabolism: Clinical and Experimental · 2026 · Same journal
• The endogenous ghrelin antagonist, LEAP2, accelerates puberty onset in conditions of early obesity · Metabolism: Clinical and Experimental · 2026 · Same journal
• The effects of acute ketone monoester supplementation on brain insulin responsiveness and cognitive performance: Results of a randomized, double-blind, placebo-controlled crossover trial in older men with overweight · Metabolism: Clinical and Experimental · 2026 · Same journal
• SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights · Metabolism: Clinical and Experimental · 2026 · Same journal
• Data leakage and overadjustment bias in proteomic prediction models of mortality among cardiovascular-kidney-metabolic syndrome stage 0–3 · Metabolism: Clinical and Experimental · 2026 · Same journal
• Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses · Metabolism: Clinical and Experimental · 2026 · Same journal